Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other financing activities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other financing activities for 13 consecutive years, with $283000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 87.42% to $283000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 10.9% year-over-year, with the annual reading at $576000.0 for FY2025, 110.99% up from the prior year.
  • Other financing activities for Q4 2025 was $283000.0 at Aytu Biopharma, up from $114000.0 in the prior quarter.
  • The five-year high for Other financing activities was $3.1 million in Q4 2022, with the low at -$4.4 million in Q2 2021.
  • Average Other financing activities over 5 years is $345888.9, with a median of $228000.0 recorded in 2024.
  • The sharpest move saw Other financing activities tumbled 333.16% in 2021, then skyrocketed 45000.0% in 2023.
  • Over 5 years, Other financing activities stood at $1.2 million in 2021, then soared by 149.55% to $3.1 million in 2022, then plummeted by 73.26% to $820000.0 in 2023, then plummeted by 81.59% to $151000.0 in 2024, then surged by 87.42% to $283000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $283000.0, $114000.0, and $576000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.